Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Key Takeaways

• Glaukos showcases Epioxa, first epithelium‑on CXL therapy
• Multiple 12‑month outcomes for MIGS stents presented
• New keratoconus screening device design reviewed
• iDose TR implant data featured in several abstracts
• ASCRS symposium draws leading ophthalmic experts

Pulse Analysis

The ASCRS annual meeting is the premier gathering for anterior‑segment surgeons, and Glaukos’ decision to anchor its scientific program there signals confidence in its pipeline. By coupling a booth presence with a dedicated symposium on Epioxa™, the company not only educates clinicians on the only FDA‑approved epithelium‑on corneal cross‑linking therapy but also leverages the event’s media reach to differentiate its corneal portfolio from competitors that rely on traditional epithelium‑off protocols. This strategic exposure is likely to drive referral patterns and boost adoption rates among ophthalmologists treating keratoconus, especially given the therapy’s streamlined, oxygen‑enriched delivery system.

Glaukos also uses the platform to showcase robust data on its MIGS and drug‑delivery technologies. Abstracts detailing 12‑month outcomes for third‑generation trabecular micro‑bypass stents and real‑world results combining these stents with the travoprost intracameral implant (iDose TR) highlight a shift toward minimally invasive, dropless glaucoma management. Such evidence addresses longstanding concerns about patient adherence and surgical safety, positioning Glaukos as a front‑runner in the evolving glaucoma market where physicians increasingly favor procedures that reduce medication burden while maintaining intraocular pressure control.

From an investor perspective, the breadth of Glaukos’ presentations—spanning glaucoma, corneal disease, and retinal applications—reinforces the company’s diversified revenue streams and long‑term growth narrative. The inclusion of a novel keratoconus screening device design further signals a pipeline that extends beyond therapeutics into diagnostic innovation. As reimbursement frameworks evolve to favor value‑based care, Glaukos’ dropless, long‑acting solutions could capture premium pricing and broader payer acceptance, potentially accelerating revenue expansion beyond its 2024 iDose TR launch. The ASCRS showcase thus serves as both a scientific forum and a market‑positioning catalyst for the company’s next phase of growth.